WithdrawnPhase 4

Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection

Stopped: unfavorable opinion of the ethics committee

France0Started 2020-04-20

Plain-language summary

The current sars-cov-2 epidemic is responsible for severe respiratory infections leading to end-of-life situations. Dexmedetomidine may be indicated in mild to moderate sedation in palliative patients, due to its pharmacological characteristics. The hypothesis of this study is that Dexmedetomidine would allow effective and safe light sedation in patients with respiratory failure in palliative situations suffering from Covid-19 infection.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Major patient
✓. Relating to palliative care
✓. With sars-cov-2 infection
✓. Requiring light to moderate sedation corresponding to a RASS score of -1 to -3

Exclusion criteria

✕. Pregnant, lactating woman.
✕. Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of the summary of product characteristics
✕. Advanced heart block (level 2 or 3) unless a pacemaker.
✕. Uncontrolled hypotension.
✕. Acute cerebrovascular pathologies.
✕. Use of other sedative drugs

What they're measuring

Efficacy of mild to moderate palliative sedation induced by Dexmedetomidine.

Timeframe: Day 30

Trial details

NCT IDNCT04350086

SponsorUniversity Hospital, Limoges

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-11-20

View on ClinicalTrials.gov More COVID-19 Infection trials